“Thrombocytopenia – Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Thrombocytopenia – Pipeline Review, H1 2015’, provides an overview of the Thrombocytopenia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products
Reasons to buy
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”
“Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thrombocytopenia Overview 8
Therapeutics Development 9
Pipeline Products for Thrombocytopenia – Overview 9
Pipeline Products for Thrombocytopenia – Comparative Analysis 10
Thrombocytopenia – Therapeutics under Development by Companies 11
Thrombocytopenia – Therapeutics under Investigation by Universities/Institutes 15
Thrombocytopenia – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Thrombocytopenia – Products under Development by Companies 19
Thrombocytopenia – Products under Investigation by Universities/Institutes 22
Thrombocytopenia – Companies Involved in Therapeutics Development 23
Ablynx NV 23
Anthera Pharmaceuticals‚ Inc. 24
Archemix Corp. 25
Arcturus Therapeutics, Inc 26
aTyr Pharma, Inc. 27
Bayer AG 28
BioLineRx, Ltd. 29
Boehringer Ingelheim GmbH 30
Bolder Biotechnology, Inc. 31
Bristol-Myers Squibb Company 32
Cellerant Therapeutics, Inc. 33
Eisai Co., Ltd. 34
GlaxoSmithKline Plc 35
Glenmark Pharmaceuticals Ltd. 36
HanAll Biopharma Co., Ltd. 37
Immunomedics, Inc. 38
InvivoGen Therapeutics 39
Jiangsu Hengrui Medicine Co., Ltd. 40
Kaketsuken K.K. 41
Merck & Co., Inc. 42
Momenta Pharmaceuticals, Inc. 43
Myelo Therapeutics GmbH 44
Neumedicines Inc. 45
Novartis AG 46
Octapharma AG 47
Omeros Corporation 48
Pfizer Inc. 49
PhytoHealth Corporation 50
Portola Pharmaceuticals, Inc. 51
Prophylix Pharma AS 52
Protalex, Inc. 53
Rigel Pharmaceuticals, Inc. 54
Shionogi & Co., Ltd. 55
STATegics, Inc. 56
ViroMed Co., Ltd. 57
Thrombocytopenia – Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 61
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
Antibody for Autoimmune Disorders and Inflammation – Drug Profile 67
ARC-15105 – Drug Profile 68
avatrombopag – Drug Profile 69
BAX-930 – Drug Profile 71
BBT-030 – Drug Profile 73
BBT-045 – Drug Profile 74
BI-655064 – Drug Profile 75
BL-8040 – Drug Profile 76
blisibimod – Drug Profile 78
BMS-986004 – Drug Profile 81
caplacizumab – Drug Profile 82
CLT-009 – Drug Profile 84
eltrombopag olamine – Drug Profile 85
fostamatinib disodium – Drug Profile 88
GBR-600 – Drug Profile 91
Gene Therapy for Chemotherapy-Induced Thrombocytopenia – Drug Profile 92
GL-2045 – Drug Profile 93
GSK-2285921 – Drug Profile 94
Hetrombopag Olamine – Drug Profile 96
HL-161 – Drug Profile 97
LUNAR-TPO – Drug Profile 98
lusutrombopag – Drug Profile 99
MK-8723 – Drug Profile 100
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders – Drug Profile 101
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders – Drug Profile 102
Myelo-001 – Drug Profile 104
NMIL-121 – Drug Profile 105
Oligonucleotides to Activate miRNA-150 for Thrombocytopenia – Drug Profile 107
OMS-721 – Drug Profile 108
PEG-VM501 – Drug Profile 110
PHN-013 – Drug Profile 111
plasma (human) – Drug Profile 112
PRT-060318 – Drug Profile 113
PRTX-100 – Drug Profile 114
rivaroxaban – Drug Profile 116
SM-101 – Drug Profile 121
STST-4 – Drug Profile 124
Tmax – Drug Profile 125
Tromplate – Drug Profile 126
TXA-302 – Drug Profile 127
veltuzumab – Drug Profile 129
Thrombocytopenia – Recent Pipeline Updates 132
Thrombocytopenia – Dormant Projects 173
Thrombocytopenia – Discontinued Products 176
Thrombocytopenia – Product Development Milestones 177
Featured News & Press Releases 177
Appendix 184
Methodology 184
Coverage 184
Secondary Research 184
Primary Research 184
Expert Panel Validation 184
Contact Us 184
Disclaimer 185″
“List of Tables
Number of Products under Development for Thrombocytopenia, H1 2015 12
Number of Products under Development for Thrombocytopenia – Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Thrombocytopenia – Pipeline by Ablynx NV, H1 2015 26
Thrombocytopenia – Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015 27
Thrombocytopenia – Pipeline by Archemix Corp., H1 2015 28
Thrombocytopenia – Pipeline by Arcturus Therapeutics, Inc, H1 2015 29
Thrombocytopenia – Pipeline by aTyr Pharma, Inc., H1 2015 30
Thrombocytopenia – Pipeline by Bayer AG, H1 2015 31
Thrombocytopenia – Pipeline by BioLineRx, Ltd., H1 2015 32
Thrombocytopenia – Pipeline by Boehringer Ingelheim GmbH, H1 2015 33
Thrombocytopenia – Pipeline by Bolder Biotechnology, Inc., H1 2015 34
Thrombocytopenia – Pipeline by Bristol-Myers Squibb Company, H1 2015 35
Thrombocytopenia – Pipeline by Cellerant Therapeutics, Inc., H1 2015 36
Thrombocytopenia – Pipeline by Eisai Co., Ltd., H1 2015 37
Thrombocytopenia – Pipeline by GlaxoSmithKline Plc, H1 2015 38
Thrombocytopenia – Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 39
Thrombocytopenia – Pipeline by HanAll Biopharma Co., Ltd., H1 2015 40
Thrombocytopenia – Pipeline by Immunomedics, Inc., H1 2015 41
Thrombocytopenia – Pipeline by InvivoGen Therapeutics, H1 2015 42
Thrombocytopenia – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 43
Thrombocytopenia – Pipeline by Kaketsuken K.K., H1 2015 44
Thrombocytopenia – Pipeline by Merck & Co., Inc., H1 2015 45
Thrombocytopenia – Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 46
Thrombocytopenia – Pipeline by Myelo Therapeutics GmbH, H1 2015 47
Thrombocytopenia – Pipeline by Neumedicines Inc., H1 2015 48
Thrombocytopenia – Pipeline by Novartis AG, H1 2015 49
Thrombocytopenia – Pipeline by Octapharma AG, H1 2015 50
Thrombocytopenia – Pipeline by Omeros Corporation, H1 2015 51
Thrombocytopenia – Pipeline by Pfizer Inc., H1 2015 52
Thrombocytopenia – Pipeline by PhytoHealth Corporation, H1 2015 53
Thrombocytopenia – Pipeline by Portola Pharmaceuticals, Inc., H1 2015 54
Thrombocytopenia – Pipeline by Prophylix Pharma AS, H1 2015 55
Thrombocytopenia – Pipeline by Protalex, Inc., H1 2015 56
Thrombocytopenia – Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 57
Thrombocytopenia – Pipeline by Shionogi & Co., Ltd., H1 2015 58
Thrombocytopenia – Pipeline by STATegics, Inc., H1 2015 59
Thrombocytopenia – Pipeline by ViroMed Co., Ltd., H1 2015 60
Assessment by Monotherapy Products, H1 2015 61
Number of Products by Stage and Target, H1 2015 63
Number of Products by Stage and Mechanism of Action, H1 2015 65
Number of Products by Stage and Route of Administration, H1 2015 67
Number of Products by Stage and Molecule Type, H1 2015 69
Thrombocytopenia Therapeutics – Recent Pipeline Updates, H1 2015 135
Thrombocytopenia – Dormant Projects, H1 2015 176
Thrombocytopenia – Dormant Projects (Contd..1), H1 2015 177
Thrombocytopenia – Dormant Projects (Contd..2), H1 2015 178
Thrombocytopenia – Discontinued Products, H1 2015 179″
“List of Figures
Number of Products under Development for Thrombocytopenia, H1 2015 12
Number of Products under Development for Thrombocytopenia – Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Products, H1 2015 21
Assessment by Monotherapy Products, H1 2015 61
Number of Products by Top 10 Targets, H1 2015 62
Number of Products by Stage and Top 10 Targets, H1 2015 62
Number of Products by Top 10 Mechanism of Actions, H1 2015 64
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64
Number of Products by Top 10 Routes of Administration, H1 2015 66
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 66
Number of Products by Top 10 Molecule Types, H1 2015 68
Number of Products by Stage and Top 10 Molecule Types, H1 2015 68″
“Ablynx NV
Anthera Pharmaceuticals‚ Inc.
Archemix Corp.
Arcturus Therapeutics, Inc
aTyr Pharma, Inc.
Bayer AG
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Cellerant Therapeutics, Inc.
Eisai Co., Ltd.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
HanAll Biopharma Co., Ltd.
Immunomedics, Inc.
InvivoGen Therapeutics
Jiangsu Hengrui Medicine Co., Ltd.
Kaketsuken K.K.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Myelo Therapeutics GmbH
Neumedicines Inc.
Novartis AG
Octapharma AG
Omeros Corporation
Pfizer Inc.
PhytoHealth Corporation
Portola Pharmaceuticals, Inc.
Prophylix Pharma AS
Protalex, Inc.
Rigel Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
STATegics, Inc.
ViroMed Co., Ltd.”
